|
| Press Releases |
|
 |
|
| Tuesday, December 1, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Monday, November 30, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Wednesday, November 11, 2020 |
|
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
| Monday, November 2, 2020 |
|
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
| BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Kingsoft Announces 2022 Annual and Fourth Quarter Results
Mar 22, 2023 10:09: JST
|
|
|
Accurate Background Acquires Australia's VerifyNow
Mar 22, 2023 10:07 HKT/SGT
|
|
|
金山软件公布2022年全年及第四季度业绩
Mar 22, 2023 09:00 HKT/SGT
|
|
|
金山軟件公佈2022年全年及第四季度業績
Mar 22, 2023 08:59 HKT/SGT
|
|
|
Kingsoft Announces 2022 Annual and Fourth Quarter Results
Mar 22, 2023 08:58 HKT/SGT
|
|
|
Freedom Business Summit 2023 brings together 5000+ entrepreneurs, freedom seekers and global citizens from all over the world
Mar 22, 2023 08:13 HKT/SGT
|
|
|
Infocus International Relaunches Online Workshop on Human Capital, Succession Planning, Talent & Performance Management
Mar 22, 2023 08:00 HKT/SGT
|
|
|
Tradition Meets Innovation - A Digital Certificate for Authentic Italian Products
Mar 21, 2023 22:00 HKT/SGT
|
|
|
Tradition Meets Innovation - A Digital Certificate for Authentic Italian Products
Mar 21, 2023 22:00 HKT/SGT
|
|
|
亨得利2022全年业绩发布
Mar 21, 2023 21:17 HKT/SGT
|
|
|
亨得利2022全年業績發佈
Mar 21, 2023 21:16 HKT/SGT
|
|
|
Hengdeli Announces 2022 Annual Results
Mar 21, 2023 21:15 HKT/SGT
|
|
|
Accurate Background Acquires Australia's VerifyNow
Mar 21, 2023 21:01 HKT/SGT
|
|
|
With U.S. Health Systems Under Growing Pressure to Fill Staff Vacancies, CGFNS Alliance Releases Updated Standards for Ethical Recruitment of Foreign Health Workers
Mar 21, 2023 19:00 HKT/SGT
|
|
|
Global Digital Payments Leader, Visa joins Dubai FinTech Summit as Co-host
Mar 21, 2023 18:30 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
